<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">The Clinician</journal-id><journal-title-group><journal-title xml:lang="en">The Clinician</journal-title><trans-title-group xml:lang="ru"><trans-title>Клиницист</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1818-8338</issn><issn publication-format="electronic">2412-8775</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">340</article-id><article-id pub-id-type="doi">10.17650/1818-8338-2018-12-1-43-50</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>CASE REPORT</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ОПИСАНИЕ СЛУЧАЯ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">SYSTEMIC VASCULITIS WITH LESION OF LARGE VESSELS AS A CAUSE OF ART ERIAL HYPERT ENSION IN A PATIENT OF YOUNG AGE</article-title><trans-title-group xml:lang="ru"><trans-title>СИСТЕМНЫЙ ВАСКУЛИТ С ПОРАЖЕНИЕМ КРУПНЫХ СОСУДОВ КАК ПРИЧИНА АРТЕРИАЛЬНОЙ ГИПЕРТЕНЗИИ У ПАЦИЕНТКИ МОЛОДОГО ВОЗРАСТА</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8266-6022</contrib-id><name-alternatives><name xml:lang="en"><surname>Andriyashkina</surname><given-names>D. Yu.</given-names></name><name xml:lang="ru"><surname>Андрияшкина</surname><given-names>Д. Ю.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Acad. A. I. Nesterov Department of Faculty Therapy</p><p><italic>1 Ostrovityanova St., Moscow 117997</italic></p><p> </p></bio><bio xml:lang="ru"><p><bold>Дарья Юрьевна Андрияшкина </bold></p><p>Кафедра факультетской терапии им. акад. А. И. Нестерова</p><p><italic>117997 Москва, ул. Островитянова, 1 </italic></p></bio><email>andryashkina.darya@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6890-8777</contrib-id><name-alternatives><name xml:lang="en"><surname>Demidova</surname><given-names>N. A.</given-names></name><name xml:lang="ru"><surname>Демидова</surname><given-names>Н. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Acad. A. I. Nesterov Department of Faculty Therapy</p><p><italic>1 Ostrovityanova St., Moscow 117997</italic></p></bio><bio xml:lang="ru"><p>Кафедра факультетской терапии им. акад. А. И. Нестерова</p><p><italic>117997 Москва, ул. Островитянова, 1 </italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4669-1006</contrib-id><name-alternatives><name xml:lang="en"><surname>Shostak</surname><given-names>N. А.</given-names></name><name xml:lang="ru"><surname>Шостак</surname><given-names>Н. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Acad. A. I. Nesterov Department of Faculty Therapy</p><p><italic>1 Ostrovityanova St., Moscow 117997</italic></p></bio><bio xml:lang="ru"><p>Кафедра факультетской терапии им. акад. А. И. Нестерова</p><p><italic>117997 Москва, ул. Островитянова, 1 </italic></p><p> </p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8874-3663</contrib-id><name-alternatives><name xml:lang="en"><surname>Somov</surname><given-names>D. V.</given-names></name><name xml:lang="ru"><surname>Сомов</surname><given-names>Д. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Acad. A. I. Nesterov Department of Faculty Therapy</p><p><italic>1 Ostrovityanova St., Moscow 117997</italic></p></bio><bio xml:lang="ru"><p>Кафедра факультетской терапии им. акад. А. И. Нестерова</p><p><italic>117997 Москва, ул. Островитянова, 1 </italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3581-3784</contrib-id><name-alternatives><name xml:lang="en"><surname>Laperishvili</surname><given-names>М. A.</given-names></name><name xml:lang="ru"><surname>Лаперишвили</surname><given-names>М. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Acad. A. I. Nesterov Department of Faculty Therapy</p><p><italic>1 Ostrovityanova St., Moscow 117997</italic></p></bio><bio xml:lang="ru"><p>Кафедра факультетской терапии им. акад. А. И. Нестерова</p><p><italic>117997 Москва, ул. Островитянова, 1 </italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">N. I. Pirogov Russian National Research Medical University, Ministry of Health of Russia</institution></aff><aff><institution xml:lang="ru">ФГБОУ ВО «Российский национальный исследовательский медицинский университет им. Н. И. Пирогова» Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2018-01-15" publication-format="electronic"><day>15</day><month>01</month><year>2018</year></pub-date><volume>12</volume><issue>1</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>43</fpage><lpage>50</lpage><history><date date-type="received" iso-8601-date="2018-07-17"><day>17</day><month>07</month><year>2018</year></date><date date-type="accepted" iso-8601-date="2018-07-17"><day>17</day><month>07</month><year>2018</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2018, Andriyashkina D.Y., Demidova N.A., Shostak N.А., Somov D.V., Laperishvili М.A.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2018, Андрияшкина Д.Ю., Демидова Н.А., Шостак Н.А., Сомов Д.В., Лаперишвили М.А.</copyright-statement><copyright-year>2018</copyright-year><copyright-holder xml:lang="en">Andriyashkina D.Y., Demidova N.A., Shostak N.А., Somov D.V., Laperishvili М.A.</copyright-holder><copyright-holder xml:lang="ru">Андрияшкина Д.Ю., Демидова Н.А., Шостак Н.А., Сомов Д.В., Лаперишвили М.А.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://klinitsist.abvpress.ru/Klin/article/view/340">https://klinitsist.abvpress.ru/Klin/article/view/340</self-uri><abstract xml:lang="en"><p><bold>Objective: </bold>to analyze and present a clinical case of late diagnosis of Takayasu’s arteritis in a young female patient with long-term arterial hypertension.</p><p><bold>Materials and methods. </bold>The female patient G., born in 1989, had noted elevated arterial pressure (AP) of 150/90 mm Hg since she was 14. At 21 the following diagnosis was stated: Fibro-muscular dysplasia, stenosis of the left renal artery. Stenosis of the celiac trunk. Aneurisms of the branches of the superior mesenteric artery; prosthesis of the left renal artery was performed. Since the beginning of 2016, the patient has noted elevated AP of 200/110 mm Hg despite continuing hypotensive therapy. Diagnosis of Nonspecific aortoarteritis was proposed in May of 2017. Methylprednisolone therapy was administered: 250 mg No. 2 intravenously, Prednisolone: 25 mg a day orally. Due to signs of decreased blood flow to the left kidney, in August of 2017 extracorporeal repeat prosthesis of the left renal artery, bypass of the right middle renal artery with reversed autovein were performed.</p><p><bold>Results. </bold>During examination in October of 2017, the patient complained of weakness, frequent elevated AP of 200/110 mm Hg. In blood test: hemoglobin 106 g/l, erythrocyte sedimentation rate 38 mm/h, C-reactive protein 25 mg/l. A heterozygous mutation in the methylenetetrahydropholate reductase, a heterozygous mutation in the factor V gene (G1691A) were identified. Homocysteine level was normal, infection and oncological pathology were excluded. The following diagnosis was made: Takayasu»s arteritis type IV affecting the aorta and its branches, moderate activity. Occlusion of the celiac trunk. Aneurisms of the branches of the superior mesenteric artery. Critical stenosis of the left renal artery. Thrombosis of the aorto-renal prosthesis. Hypoplasia of the left kidney. Prednisolone 50 mg a day, metoprolol 50 mg a day, valsartan 160 mg a day, acetylsalicylic acid 100 mg a day were prescribed.</p><p><bold>Conclusion. </bold>The presented clinical observation shows the importance of comprehensive examination of young patients complaining of elevated AP for many years. Due to untimely diagnosis and absence of pathogenetic therapy, the patient suffered negative consequences of surgical treatment.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Цель исследования </bold>– анализ и представление клинического случая поздней диагностики артериита Такаясу у больной молодого возраста, длительно страдавшей артериальной гипертензией.</p><p><bold>Материалы и методы. </bold>Пациентка Г., 1989 г. р., отмечает повышение артериального давления (АД) до 150/90 мм рт. ст. с 14 лет. В 21 год установлен диагноз «фиброзно-мышечная дисплазия, стеноз левой почечной артерии. Стеноз чревного ствола. Аневризмы ветвей верхней брыжеечной артерии». Проведено протезирование левой почечной артерии. С начала 2016 г. больная стала отмечать повышение АД до 200/110 мм рт. ст. на фоне постоянной гипотензивной терапии. Диагноз «неспецифический аортоартериит» предположен в мае 2017 г. Проведена терапия метилпреднизолоном – 250 мг внутривенно № 2, преднизолон – 25 мг/сут перорально. В связи с признаками выраженного снижения кровотока левой почки в августе 2017 г. выполнены экстракорпоральное репротезирование левой почечной артерии, аорто-почечное шунтирование правой средней почечной артерии реверсированной аутовеной.</p><p><bold>Результаты. </bold>При обследовании в октябре 2017 г. – жалобы на слабость, частое повышение АД до 200/110 мм рт. ст. В анализах крови: гемоглобин – 106 г/л, скорость оседания эритроцитов – 38 мм/ч, С-реактивный белок – 25 мг/л. Выявлены гетерозиготная мутация в гене метилентетрагидрофолатредуктазы, гетерозиготная мутация в гене V фактора (G1691A). Уровень гомоцистеина в норме, исключена инфекционная и онкопатология. Сформулирован диагноз «артериит Такаясу IV типа, c поражением аорты и ее ветвей, умеренная активность. Окклюзия чревного ствола. Аневризмы ветвей верхней брыжеечной артерии. Критический стеноз левой почечной артерии. Тромбоз аорто-почечного протеза. Гипоплазия левой почки». Назначены преднизолон 50 мг/ сут, метопролол 50 мг/ сут, валсартан 160 мг/ сут, ацетилсалициловая кислота 100 мг/сут.</p><p><bold>Заключение. </bold>Представленное клиническое наблюдение показывает, насколько важно всесторонне обследовать пациента молодого возраста с жалобой на повышение АД в течение многих лет. В связи с несвоевременно поставленным диагнозом и отсутствием патогенетической терапии у пациентки возникли неблагоприятные последствия хирургического лечения.</p></trans-abstract><kwd-group xml:lang="en"><kwd>Takayasu’s arteritis</kwd><kwd>pulseless disease</kwd><kwd>abdominal aorta aneurism</kwd><kwd>renal artery stenosis</kwd><kwd>renovascular hypertension</kwd><kwd>hematogenic thrombophilia</kwd><kwd>prednisolone</kwd><kwd>tumor necrosis factor alpha inhibitors</kwd><kwd>interleukin-6 inhibitors</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>артериит Такаясу</kwd><kwd>болезнь отсутствия пульса</kwd><kwd>аневризма брюшного отдела аорты</kwd><kwd>стеноз почечных артерий</kwd><kwd>вазоренальная гипертензия</kwd><kwd>гематогенная тромбофилия</kwd><kwd>преднизолон</kwd><kwd>ингибиторы фактора некроза опухоли альфа</kwd><kwd>ингибиторы интерлейкина-6</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Omura M., Saito J., Yamaguchi K. et al. Prospective study on the prevalence of secondary hypertension among hypertensive patients visiting a general outpatient clinic in Japan. Hypertens Res 2004;27(3):193–202.</mixed-citation></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">Chikhladze N. M., Chazova I. E. Secondary forms of arterial hypertension. Kardiologiya = Cardiology 2011;1(60): 5–10. (In Russ.).</mixed-citation><mixed-citation xml:lang="ru">Чихладзе Н. М., Чазова И. Е. Вторичные формы артериальной гипертензии. Кардиология 2011;1(60):5–10.</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><mixed-citation>Safian R. D., Textor S. C. Renalarterystenosis. N Engl J Med 2001;344(6):431–42.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Töpel I., Zorger N., Steinbauer M. Inflammatory diseases of the aorta: Part 1: Non-infectious aortitis. Gefasschirurgie 2016;21(Suppl 2):80–6.</mixed-citation></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">Federal clinical recommendations on medical care for children with nonspecific aortoarteritis. Ministry of Health of Russia, 2015. 23 p. Available at: http://www.pediatr-russia.ru/sites/ default/files/file/kr_ao.pdf. (In Russ.).</mixed-citation><mixed-citation xml:lang="ru">Федеральные клинические рекомендации по оказанию медицинской помощи детям с неспецифическим аортоартериитом. МЗ РФ, 2015. 23 c. Доступно по: http://www.pediatr-russia. ru/sites/default/files/file/kr_ao.pdf.</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><mixed-citation>Min P. K., Park S., Jung J. H. et al. Endovascular therapy combined with immunosuppressive treatment for occlusive arterial disease in patients with Takayasu’s arteritis. J Endovasc Ther 2005;12(1):28–34.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Hata A., Noda M., Moriwaki R., Numano F. Angiographic findings of Takayasu arteritis: new classification. Int J Cardiol 1996;54(Suppl): S155–63.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Moriwaki R., Noda M., Yajima M. et al. Clinical manifestations of Takayasu arteritis in India and Japan – new classification of angiographic findings. Angiology 1997;48(5):369–79.</mixed-citation></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">Mukhin N. A., Smitienko I. O., Novikov P. I. Takayasu’s arteritis: diagnostic difficulties, treatment and outcomes in a cohort study of 128 patients. Klinicheskaya farmakologiya i terapiya = Clinical Pharmacology and Therapy 2014;23(3):55–61. (In Russ.).</mixed-citation><mixed-citation xml:lang="ru">Мухин Н. А., Смитиенко И. О., Новиков П. И. Артериит Такаясу: трудности диагностики, лечение и исходы в когортном исследовании у 128 больных. Клиническая фармакология и терапия 2014;23(3):55–61.</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><mixed-citation>Vanoli M., Bacchiani G., Origgi L., Scorza R. Takayasu’s arteritis: a changing disease. J Nephrol 2001;14(6):497–505.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Qi Y., Yang L., Zhang H. et al. The presentation and management of hypertension in a large cohort of Takayasu arteritis. Clin Rheumatol 2017. DOI: 10.1007/s10067‑017‑3947‑4.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Park M. C., Lee S. W., Park Y. B. et al. Clinical characteristics and outcomes of Takayasu’s arteritis: analysis of 108 patients using standardized criteria for diagnosis, activity assessment, and angiographic classification. Scand J Rheumatol 2005;34(4):284–92.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Wen D., Du X., Ma C. S. Takayasu arteritis: diagnosis, treatment and prognosis. Int Rev Immunol 2012;31: 462–73.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Ishihara T., Haraguchi G., Tezuka D. et al. Diagnosis and assessment of Takayasu arteritis by multiple biomarkers. Circ J 2013;77(2):477–83.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Dagna L., Salvo F., Tiraboschi M. et al. Pentraxin-3 as a marker of disease activity in Takayasu arteritis. Ann Intern Med 2011;155(7):425–33.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Karageorgaki Z. T., Bertsias G. K., Mavragani C. P. et al. Takayasu features in Greece. Clin Exp Rheumotol 2009;27(1):833–9.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Halefoglu A. M. Yakut S. Role of magnetic resonance imaging in the early diagnosis of Takayasu arteritis. Australas Radiol 2005;49:377–81.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Duftner C., Dejaco C., Sepriano A. et al. Imaging in diagnosis, outcome prediction and monitoring of large vessel vasculitis: a systematic literature review and metaanalysis informing the EULAR recommendations. RMD Open 2018;4(1):e000612. DOI: 10.1136/rmdopen-2017-000612.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Direskeneli H., Aydin S., Merkel P. Assessment of disease activity and progression in Takayasu’s arteritis. Clin Exp Rheumatol 2011;29 (1 Suppl 64):S86–91.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Slart RHJA, Writing group, Reviewer group et al. FDG-PET/CT (A) imaging in large vessel vasculitis and polymyalgia rheumatica: joint procedural recommendation of the EANM, SNMMI, and the PET Interest Group (PIG), and endorsed by the ASNC. Eur J Nucl Med Mol Imaging. 2018;45(7):1250–69. DOI: 10.1007/s00259‑018‑3973‑8.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice. Аnn Rheum Dis 2018. PII: annrheumdis-2017–212649. DOI: 10.1136/annrheumdis-2017-212649.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Fields C. E., Bower T. C., Cooper L. T. et al. Takayasu’s arteritis: operative results and influence of disease activity. J Vasc Surg. 2006;43(1):64–71.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Saadoun D., Lambert M., Mirault T. et al. Retrospective analysis of surgery versus endovascular intervention in Takayasu arteritis: a multicenter experience. Circulation 2012;125(6):813–9.</mixed-citation></ref><ref id="B24"><label>24.</label><citation-alternatives><mixed-citation xml:lang="en">РRussian clinical guidelines. Rheumatology. Ed. E. L. Nasonov. Moscow: GEOTAR-Media, 2017. 464 p. (In Russ.).</mixed-citation><mixed-citation xml:lang="ru">Российские клинические рекомендации. Ревматология. Под ред. Е. Л. Насонова. М.: ГЭОТАР-Медиа, 2017. 464 c.</mixed-citation></citation-alternatives></ref><ref id="B25"><label>25.</label><citation-alternatives><mixed-citation xml:lang="en">Novikov P. I., Smitienko I. O., Moiseev S. V. Effectiveness of long-term treatment with tumor necrosis factor-α inhibitors in Takayasu’s arteritis. Klinicheskaya farmakologiya i terapiya = Clinical Pharmacology and Therapy 2013;22(2):44–8. (In Russ.).</mixed-citation><mixed-citation xml:lang="ru">Новиков П. И., Смитиенко И. О., Моисеев С. В. Эффективность продолжительного лечения ингибиторами фактора некроза опухоли-α при артериите Такаясу, рефрактерном к стандартной иммуносупрессивной терапии. Клиническая фармакология и терапия 2013;22(2):44–8.</mixed-citation></citation-alternatives></ref><ref id="B26"><label>26.</label><mixed-citation>Gudbrandsson B., Molberg О., Palm О. TNF inhibitors appear to inhibit disease progression and improve outcome in Takayasu arteritis; an observational, population-based time trend study. Arthritis Res Ther 2017;19(1):99. DOI: 10.1186/s13075‑017‑1316-y. PMID: 28521841.</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Kong X., Zhang X., Lv P. et al. Treatment of Takayasu arteritis with the IL-6R antibody tocilizumab vs. cyclophosphamide. Int J Cardiol 2018. PII: S0167– 5273(17)35894–1. DOI: 10.1016/j.ijcard.2017.12.066.</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Nakaoka Y., Isobe M., Takei S. Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebocontrolled, phase 3 trial in Japan (the TAKT study). Ann Rheum Dis 2018;77(3):348–54. DOI: 10.1136/annrheumdis-2017-211878.</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>García-Martínez A., Prieto-González S., Arguis P. et al. Aortitis and Aortic Aneurysmin Systemic Vasculitis. 2011. Available at https://www.intechopen.com/books/etiology-pathogenesis-andpathophysiologyof-aortic-aneurysmsandaneurysm-rupture</mixed-citation></ref></ref-list></back></article>
